Predictive biomarkers in metastatic kidney cancer

A review published in European Urology Focus looks at tools to optimise the choice and sequence of treatments to ensure the best clinical benefit for their metastatic renal cell carcinoma (RCC) patients. The review concludes that the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is currently the only validated tool that can […]

read more

First immunotherapy combination of ipilimumab plus nivolumab available to patients in England

We are very pleased to learn that the ipilimumab plus nivolumab combination has been endorsed for use by the National Institute for Health and Care Excellence (NICE) for poor- and intermediate-risk advanced renal cell carcinoma (RCC). The treatment will be made immediately available to patients in England via the Cancer Drugs Fund. The availability of […]

read more

ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer

New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients […]

read more

Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months

Further survival data has been released from the phase 3 CheckMate-214 study, showing that treatment with a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to demonstrate long-term survival benefits in patients with previously untreated advanced/metastatic renal cell carcinoma (RCC) after 30 months follow-up. Patients with intermediate- and poor-risk untreated RCC treated with the nivolumab/ipilimumab […]

read more

ESOU 2019: First-line treatment for metastatic renal cell carcinoma – where do we stand?

The following review of the literature for first-line treatment of metastatic renal cell carcinoma (RCC) was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. The current paradigm for the first- and second-line treatment of RCC was presented based upon patient risk according to the International Metastatic Renal […]

read more

European Commission approves nivolumab plus ipilimumab combination for first-line advanced RCC

The European Commission has approved the nivolumab plus ipilimumab combination for first-line treatment of people with intermediate- and poor-risk advanced renal cell carcinoma (RCC). This is the first approval of a combination of immunotherapy agents for untreated advance RCC in the European Union. This approval offers advanced RCC patients in Europe a first-line treatment with a […]

read more

Personalised vaccine to be tested in patients with kidney cancer

Scientists at the Dana-Farber Cancer Institute in Boston, USA, are testing a new personalised cancer vaccine, called NeoVax, for the treatment of kidney cancer patients at high risk of recurrence following surgery. The vaccine incorporates proteins (neoantigens) that are specific to the cancer cells in each individual’s tumour. The vaccine is then linked to a […]

read more

Nivolumab-ipilimumab combination delays the need for additional treatment in kidney cancer patients

A recent analysis of data from the phase 3 Checkmate-214 clinical trial showed that first-line treatment with the nivolumab/ipilimumab combination significantly delayed the need for subsequent treatment in patients with advanced or metastatic renal cell carcinoma (RCC), compared with standard treatment with sunitinib. This benefit was also seen in patients who had stopped treatment, and […]

read more

First immunotherapy combination of ipilimumab plus nivolumab recommended by CHMP

We have just learnt the news that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), is recommending approval of the ipilimumab plus nivolumab combination for previously untreated patients who have intermediate- or poor-risk advanced renal cell carcinoma (RCC). The CHMP positive opinion will now be reviewed by the European Commission (EC), […]

read more

ESMO 2018: Longer treatment-free survival for ipilimumab/nivolumab combination versus sunitinib

Analysis of the phase 3 CheckMate-214 study has shown that the ipilimumab + nivolumab combination resulted in a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) than patients who were treated with the standard of care, sunitinib. Data from the CheckMate-214 study were presented at the […]

read more
Showing 11 to 20 of 54 results
  TOP